Full Press Release Details
Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021.
BIIB
Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021
Key Takeaway: Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis